Foreign Generics See Ripe Market In Price Conscious Japan
This article was originally published in PharmAsia News
Generic makers in other countries are setting their sights on Japan as the place for major expansions. Israel's Teva Pharmaceutical Industries and India's Ranbaxy Laboratories are among companies that plan to take advantage of the Japanese government's initiative to reduce the price of prescriptions. Ranbaxy has been trying to gain ground in Japan's market since it teamed with Nippon Chemiphar six years ago, but now it hopes to gain ground with its amlodipine generic of Pfizer's blockbuster Norvasc blood pressure drug. Other foreign generics planning expansions include Sandoz of Germany and Zydus Cadila of India. (Click here for more - a subscription may be required
You may also be interested in...
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.